These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34900161)

  • 1. Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis.
    Elgendy SG; Abd-Elhameed R; Daef E; Mohammed SM; Hassan HM; El-Mokhtar MA; Nasreldein A; Khedr EM
    Iran J Microbiol; 2021 Oct; 13(5):632-641. PubMed ID: 34900161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of the gut microbiome in egyptian patients with remitting relapsing multiple sclerosis.
    Mekky J; Wani R; Said SM; Ashry M; Ibrahim AE; Ahmed SM
    Mult Scler Relat Disord; 2022 Jan; 57():103354. PubMed ID: 35158462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters.
    Miyake S; Kim S; Suda W; Oshima K; Nakamura M; Matsuoka T; Chihara N; Tomita A; Sato W; Kim SW; Morita H; Hattori M; Yamamura T
    PLoS One; 2015; 10(9):e0137429. PubMed ID: 26367776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of Gut Microbiota in Alzheimer's Disease and Their Relation to the Cognitive Impairment.
    Khedr EM; Omeran N; Karam-Allah Ramadan H; Ahmed GK; Abdelwarith AM
    J Alzheimers Dis; 2022; 88(3):1103-1114. PubMed ID: 35754271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.
    Kozhieva M; Naumova N; Alikina T; Boyko A; Vlassov V; Kabilov MR
    BMC Microbiol; 2019 Dec; 19(1):309. PubMed ID: 31888483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota in early pediatric multiple sclerosis: a case-control study.
    Tremlett H; Fadrosh DW; Faruqi AA; Zhu F; Hart J; Roalstad S; Graves J; Lynch S; Waubant E;
    Eur J Neurol; 2016 Aug; 23(8):1308-1321. PubMed ID: 27176462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis.
    Pellizoni FP; Leite AZ; Rodrigues NC; Ubaiz MJ; Gonzaga MI; Takaoka NNC; Mariano VS; Omori WP; Pinheiro DG; Matheucci Junior E; Gomes E; de Oliveira GLV
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33925359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials.
    Schepici G; Silvestro S; Bramanti P; Mazzon E
    Cell Transplant; 2019 Dec; 28(12):1507-1527. PubMed ID: 31512505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of Gut Microbiota and the Brain-Immune-Intestine Axis in Patients With Relapsing-Remitting Multiple Sclerosis After Treatment With Oral Cladribine: Protocol for a Prospective Observational Study.
    van Pamelen J; van Olst L; Budding AE; ; de Vries HE; Visser LH
    JMIR Res Protoc; 2020 Jul; 9(7):e16162. PubMed ID: 32723709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls.
    Chen J; Chia N; Kalari KR; Yao JZ; Novotna M; Paz Soldan MM; Luckey DH; Marietta EV; Jeraldo PR; Chen X; Weinshenker BG; Rodriguez M; Kantarci OH; Nelson H; Murray JA; Mangalam AK
    Sci Rep; 2016 Jun; 6():28484. PubMed ID: 27346372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis.
    Sterlin D; Larsen M; Fadlallah J; Parizot C; Vignes M; Autaa G; Dorgham K; Juste C; Lepage P; Aboab J; Vicart S; Maillart E; Gout O; Lubetzki C; Deschamps R; Papeix C; Gorochov G
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33975914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota in multiple sclerosis: possible influence of immunomodulators.
    Cantarel BL; Waubant E; Chehoud C; Kuczynski J; DeSantis TZ; Warrington J; Venkatesan A; Fraser CM; Mowry EM
    J Investig Med; 2015 Jun; 63(5):729-34. PubMed ID: 25775034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multiple sclerosis gut microbiota: A systematic review.
    Mirza A; Forbes JD; Zhu F; Bernstein CN; Van Domselaar G; Graham M; Waubant E; Tremlett H
    Mult Scler Relat Disord; 2020 Jan; 37():101427. PubMed ID: 32172998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
    Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
    Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease.
    Li F; Wang M; Wang J; Li R; Zhang Y
    Front Cell Infect Microbiol; 2019; 9():206. PubMed ID: 31245306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls.
    Tremlett H; Fadrosh DW; Faruqi AA; Hart J; Roalstad S; Graves J; Spencer CM; Lynch SV; Zamvil SS; Waubant E;
    BMC Neurol; 2016 Sep; 16(1):182. PubMed ID: 27652609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between LincR-Gng2-5'and LincR-Epas1-3'as with the severity of multiple sclerosis in Egyptian patients.
    Shaker OG; Golam RM; Ayoub S; Daker LI; Elguaad MKA; Said ES; Khalil MAF
    Int J Neurosci; 2020 May; 130(5):515-521. PubMed ID: 31790618
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
    J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial.
    Storm-Larsen C; Myhr KM; Farbu E; Midgard R; Nyquist K; Broch L; Berg-Hansen P; Buness A; Holm K; Ueland T; Fallang LE; Burum-Auensen E; Hov JR; Holmøy T
    Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319888767. PubMed ID: 31798939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.